Romosozumab and estrogen for bone loss from missed periods
Treatments studied
Part of Bones, joints & muscles, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests whether a bone-building medication (romosozumab) combined with estrogen replacement therapy can improve bone density in young women with hypothalamic amenorrhea (missing periods due to low energy or stress). It aims to find a better treatment for low bone density caused by this condition.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are female and between 14 and 30 years old
- You have had less than 3 menstrual periods in the last 6 months
- A bone density test shows your bone mass is lower than normal for your age
- You do not currently smoke or vape
- You have no history of blood clots in yourself or a close family member
- You have had a dental checkup in the past year and no recent dental surgery
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how estrogen treatment affects bone strength in young women with Functional Hypothalamic Amenorrhea (FHA), a condition where periods stop due to stress, low weight, or over-exercise. Participants who have had very few periods will receive estrogen to see if it improves bone density.
This study looks at what changes in the body after starting romosozumab (an osteoporosis treatment) in postmenopausal women at higher risk for fractures. Researchers want to understand the treatment’s “mechanism,” which may help improve future osteoporosis care.
This study tests a combination of two bone-building drugs (romosozumab and teriparatide) in postmenopausal women with osteoporosis who are at high risk for fractures. The goal is to see if the combination strengthens bones faster and better than either drug alone.
This trial is testing a medicine called romosozumab to treat postmenopausal women with severe osteoporosis and a recent fracture. It aims to find the best way to use this drug to strengthen bones and prevent more fractures.
This study compares two treatments for osteoporosis in postmenopausal women: a sequence of romosozumab followed by denosumab versus zoledronic acid alone. The goal is to see which approach better improves bone density in the hip. Participants will receive either the combination or the single drug for a period, and their progress will be monitored.
This trial tests whether switching between two medications (Romosozumab and Denosumab) using a cycle or sequence schedule works better for improving bone density in postmenopausal women with severe osteoporosis. It aims to find the most effective treatment plan.
Hear when a new FHA (Functional Hypothalamic Amenorrhea) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.